Valeant (VRX) Philidor Concern Likely Misinformation - Nomura
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/12/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
Valeant Pharma (VRX) Taps Lows Below $90/Share
October 21, 2015 1:24 PM EDTValeant Pharma (NYSE: VRX) declined 38% to session lows at around 1:20 pm on Tuesday, briefly traded under $90 per share. The massive slide follows Citron Research's fraud report earlier. So far the company hasn't responded, which might be viewed as a negative by some investors.
... MoreIcahn Wishes He Was Short Valeant (VRX) Stock - CNBC
October 21, 2015 12:42 PM EDTCarl Icahn said Valeant Pharma (NYSE: VRX) is 'prime example' of inversion, according to an interview on CNBC today. Icahn also noted that he doesn't have a long position in the stock, but wishes he had a short position.
... MoreMizuho Weighs in on Panic in Specialty Pharmaceuticals Sector (VRX) (AGN) (ENDP) (SCMP) (JAZZ) (MNK)
October 21, 2015 12:39 PM EDTMizuho Securities analyst Irina Koffler offered some comments on the specialty pharmaceutical sector give the panic following reports of fraud at Valeant Pharma (NYSE: VRX).
Koffler key points are highlighted below:
Our Neutral thesis on VRX is intact: We cannot verify or dispute the allegations made by Citron Research or SIRF about Valeant's Philidor pharmacy. That said, it almost doesn't matter as the stock appears broken and management will now have to defend the story rather than focus on its organic growth and M&A. We initially used a 14% WACC... More